Cortland Associates’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-7,367
| Closed | -$213K | – | 60 |
|
|
2024
Q3 | $213K | Buy |
7,367
+83
| +1% | +$2.42K | 0.03% | 57 |
|
|
2024
Q2 | $204K | Buy |
+7,284
| New | +$201K | 0.03% | 56 |
|
|
2024
Q1 | – | Sell |
-7,342
| Closed | -$211K | – | 54 |
|
|
2023
Q4 | $211K | Buy |
7,342
+75
| +1% | +$2.27K | 0.03% | 53 |
|
|
2023
Q3 | $241K | Sell |
7,267
-69
| -0.9% | -$2.44K | 0.04% | 48 |
|
|
2023
Q2 | $269K | Sell |
7,336
-1,434
| -16% | -$55.8K | 0.04% | 49 |
|
|
2023
Q1 | $358K | Buy |
8,770
+357
| +4% | +$15.4K | 0.06% | 40 |
|
|
2022
Q4 | $431K | Sell |
8,413
-250
| -3% | -$12K | 0.07% | 38 |
|
|
2022
Q3 | $379K | Buy |
8,663
+8
| +0.1% | +$389 | 0.07% | 41 |
|
|
2022
Q2 | $454K | Buy |
8,655
+858
| +11% | +$43.7K | 0.08% | 40 |
|
|
2022
Q1 | $404K | Sell |
7,797
-100
| -1% | -$5.19K | 0.05% | 41 |
|
|
2021
Q4 | $466K | Buy |
7,897
+201
| +3% | +$9.96K | 0.05% | 43 |
|
|
2021
Q3 | $331K | Hold |
7,696
| – | – | 0.04% | 51 |
|
|
2021
Q2 | $301K | Hold |
7,696
| – | – | 0.03% | 51 |
|
|
2021
Q1 | $279K | Hold |
7,696
| – | – | 0.03% | 51 |
|
|
2020
Q4 | $283K | Sell |
7,696
-574
| -7% | -$21.1K | 0.03% | 46 |
|
|
2020
Q3 | $288K | Hold |
8,270
| – | – | 0.04% | 46 |
|
|
2020
Q2 | $257K | Buy |
8,270
+53
| +0.6% | +$1.8K | 0.04% | 46 |
|
|
2020
Q1 | $254K | Sell |
8,217
-35
| -0.4% | -$1.19K | 0.05% | 39 |
|
|
2019
Q4 | $307K | Buy |
8,252
+88
| +1% | +$3.13K | 0.04% | 40 |
|
|
2019
Q3 | $278K | Hold |
8,164
| – | – | 0.05% | 39 |
|
|
2019
Q2 | $336K | Hold |
8,164
| – | – | 0.05% | 36 |
|
|
2019
Q1 | $329K | Sell |
8,164
-5,962
| -42% | -$239K | 0.05% | 39 |
|
|
2018
Q4 | $585K | Buy |
14,126
+74
| +0.5% | +$3.07K | 0.11% | 29 |
|
|
2018
Q3 | $588K | Sell |
14,052
-38
| -0.3% | -$1.46K | 0.09% | 33 |
|
|
2018
Q2 | $485K | Sell |
14,090
-325
| -2% | -$11.1K | 0.08% | 37 |
|
|
2018
Q1 | $485K | Buy |
14,415
+122
| +0.9% | +$4.19K | 0.09% | 35 |
|
|
2017
Q4 | $491K | Buy |
14,293
+630
| +5% | +$21.5K | 0.09% | 36 |
|
|
2017
Q3 | $463K | Sell |
13,663
-592
| -4% | -$19K | 0.09% | 31 |
|
|
2017
Q2 | $454K | Buy |
14,255
+203
| +1% | +$6.4K | 0.09% | 33 |
|
|
2017
Q1 | $456K | Hold |
14,052
| – | – | 0.09% | 35 |
|
|
2016
Q4 | $433K | Sell |
14,052
-84
| -0.6% | -$2.56K | 0.09% | 38 |
|
|
2016
Q3 | $454K | Buy |
+14,136
| New | +$473K | 0.09% | 39 |
|
Other funds holding PFE
Cortland Associates's PFE Position: Q4 2024 in Review
Cortland Associates sold out of Pfizer (PFE) in Q4 2024, closing a stake of 7,367 shares — an estimated $213K sold.
Cortland Associates first reported a position in PFE in Q3 2016 and held it in 32 quarters. The position peaked at $588K in Q3 2018. 2,996 funds tracked by Wall St. Rank hold PFE as of Q4 2024.
- Cortland Associates reported no remaining Pfizer position as of Q4 2024 after selling out during the quarter.
- Cortland Associates sold 7,367 Pfizer shares in Q4 2024, an estimated $213K.
- Cortland Associates first reported a position in Pfizer in Q3 2016 and held it in 32 quarters.
- Cortland Associates's Pfizer position peaked at $588K in Q3 2018.
- 2,996 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.
Based on Cortland Associates's 13F filing for Q4 2024, filed 23 Jan 2025.